Spycher et al., ChemBioChem 2017, 18:1923-7
Steffen et al., J. Biol. Chem. 2017, 292:15622-35
Dennler et al., Chembiochem. 2015, 16:861-7
Dennler et al., Bioconjugate Chem. 2014, 25, 569-78
Kaufmann et al., Food Addit. Contam. Part. A 2012, 29:1364-73
Jeger et al., Angew. Chem. Int. Ed. Engl. 2010, 49:9995-7
Gianfrani et al., Gastroenterology 2007, 133:780-9
Pfleiderer et al., Microbiol. Res. 2005, 160:265-71
Ando et al., Agric. Biol. Chem. 1989, 53:2613-17
Pasternack et al., Eur. J. Biochem. 1998, 257:570-6
Grossowicz et al., J. Biol. Chem. 1950, 187, 111-25
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering